Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 ...

(TVTX) on Monday reported a loss of $37.1 million in its first quarter.

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

A director of Travere Therapeutics reported selling 8,000 shares in the open market on April 14, 2026, generating a transaction value of about $329,000. The sale represented 12.21% of Gary A. Lyons’s ...

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...

Travere Therapeutics recently reported quarterly results showing higher revenue and a smaller net loss than the prior year, alongside mostly positive Wall Street analyst commentary. At the same time, ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 Stocks With Monster Returns. Travere Therapeutics grew its share prices by 40.78 percent week-on-week, as investors increased their positions ...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial ...